An open-label, phase I study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of RO7227166 (a CD19 targeted 4-1BB ligand) in combination with Obinutuzumab and in combination with Glofitmab following a pre-treatment dose of Obinutuzumab administered in participants with relapsed/refractory B-Cell non-Hodgkin's lymphoma

Description

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is divided into a dose-escalation stage (Part I and Part II) and a dose expansion stage (Part III).

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT04077723 Opens a new window